ERBC group is a leader in discovery and non-clinical studies, offering to healthcare and chemical professionals a comprehensive range of discovery and preclinical models, regulatory pre-IND package and consultancy services to de-risk innovation and improve R&D productivity.
About the solution
At ERBC Group, THEY STRATEGIZE your approach to make your drug development a SUCCESS: – Build on most relevant translational models – Select best predictive biomarkers – Choose state-of-the-art technologies.
Vect-Horus is a privately held biotechnology company that designs and develops molecular vectors that facilitate targeting and delivery of therapeutic or imaging agents to organs, including the brain and tumors. Founded in 2005, Vect-Horus is a spin-off of the Institute for Neurophysiopathology (INP, UMR7051, CNRS and Aix Marseille University), formerly headed by Dr Michel Khrestchatisky, co-founder of the company. Vect-Horus has 40 employees (most in R&D).
By combining pharmaceutical agents to its vectors, VECT-HORUS enables their transport across the BBB, which significantly impedes brain delivery of most drugs. Proof of concept of the technology was demonstrated in animal models for different vectorized molecules (Oligonucleotides, Antibodies, NPs…).
Based on its potential to target specific receptors, notably those that are found at high levels in some pathological tissues, the Company is also targeting cancers (pancreatic, adrenal cancer, glioblastoma, etc.), where there is a high unmet medical need.
About the solution
VECT-HORUS discovered, validated, and optimized different families of molecular vector that target the LDL Receptor, Transferrin Receptor and undisclosed ones that allow drug targeted delivery to different organs.
The vectors are protected by several families of patents and ongoing patent applications. They have different properties (structure, affinity, stability, organ specificity) allowing adaptation of the vectorization process on a case-to-case basis.
Vect-Horus seeks to develop the broad potential of its proprietary VECTrans® technology platform through partnerships and licensing agreements with pharmaceutical and biotechnology companies in multiple therapeutic applications.
ClinSearch is a full service European CRO, established in 1999, offering clinical research and medical evaluation services throughout Europe, as well as the Middle East and the United States.
They have conducted hundreds of studies, from phase I to IV studies, early access programs, post-marketing studies, RWE, PASS, PAES, database analyses and medico-economic studies, involving 1 patient up to 220,000 subjects. Their customers include global and local medical device, biotechnology and pharmaceutical companies, as well as public health institutions.
About the solution
Full service offering from A to Z: methodological input to study design through to peer-reviewed publications, passing via in-house development of sophisticated healthcare tools (EDC, ePRO, …).
The in-house team of over 70 people work from our headquarters in Malakoff (France), but hail from ~15 different countries and speak over 10 languages, and are trained to a high standard (MD, PhD, PharmD, MS, MPH …).
By understanding complex biology through artificial intelligence, they integrate the best of human and AI capabilities to develop improved drugs and diagnostics at scale.
Through their understanding of complex biology using AI, they identify new treatments, de-risk and accelerate clinical trials, and develop diagnostic tools to reduce time to impact for patients.
Owkin was founded with this vision in mind, combining human expertise with cutting-edge technology to revolutionize the medical field.
About the solution
Owkin works with top academic centers to curate, enrich, and generate deep, multimodal data that is AI-ready.
They apply AI to multimodal, KOL-curated data to subtype patients and identify novel biomarkers to inform drug discovery, de-risk clinical trials, and develop and deploy diagnostics in clinical practice.
Their drug discovery engines leverage their expertise in AI, biology, and medicine to understand the intricate biological interactions that define specific patient subgroups. Through their AI engines, they deliver novel drug targets and optimize drug positioning.
They combine machine learning methodologies, patient data, and innovative modalities to increase the probability of success of clinical trials.
Their AI diagnostics help pre-screen for biomarkers and predict outcomes — giving healthcare providers a fuller picture of a patient’s disease. This means more patients can benefit from targeted therapies.
